PDGFR in gastrointestinal stromal tumour

1 EU-approved indication in gastrointestinal stromal tumour needs a PDGFR result: avapritinib (advanced).

Line of therapy

Approved indications, Gastrointestinal stromal tumour
DrugBiomarker requirementRegimenSettingConditions
PDGFRA mutation1
Avapritinib
Ayvakytconditional
D842V
Monotherapy
Any line
advanced
None

3 approvals for GIST need no biomarker and apply whatever the result. All approvals for GIST

See also

Label wording1

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Avapritinib (Ayvakyt)
    AYVAKYT is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation.